Andreas Burchert, MD, University of Marburg, Marburg, Germany, outlines the latest data on the optimization of transplantation outcomes for patients with acute myeloid leukemia. Dr Burchert describes how the risk of relapse currently presents the greatest challenge in the field and comments on the need to improve the rate and depth of remissions prior to transplantation. In the post-transplant setting, Dr Burchert highlights the need to have highly tolerable therapeutic options available. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.